Corbus Pharmaceuticals Holdings, Inc. appoints Nishant Saxena as chief business officer and schedules data call on CRB-701

Corbus Pharmaceuticals Holdings, Inc. appoints Nishant Saxena as chief business officer and schedules data call on CRB-701
Corbus updates leadership, sets data call

Corbus Pharmaceuticals Holdings, Inc. has appointed Nishant Saxena as its new chief business officer, marking a significant addition to the company’s leadership team.

The firm also announced it will host a conference call and webcast on Tuesday, May 26 at 8 a.m. EDT to present data from its Phase 1/2 study of CRB-701 targeting head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The event is expected to draw attention from investors and analysts ahead of the #ASCO2026 meeting.

Corbus previously announced plans to present updated Phase 1/2 results for CRB-701 at the 2026 ASCO annual meeting, drawing industry interest toward its oncology pipeline developments. The company also recently reported its 2026 first quarter financial results and provided a corporate update. Additional details are available in Corbus’s ASCO event preview and its Q1 financial update.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.